HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-septic effects of fisetin in vitro and in vivo.

Abstract
Sepsis is a state of disrupted inflammatory homeostasis that is initiated by infection. High mobility group box 1 (HMGB1) protein acting as a late mediator of severe vascular inflammatory conditions, such as sepsis and endothelial cell protein C receptor (EPCR), is involved in vascular inflammation. Fisetin, an active compound from the family Fabaceae, was reported to have antiviral, neuroprotective, and anti-inflammatory activities. Here, we determined the anti-septic effects of fisetin on HMGB1-mediated inflammatory responses and on the shedding of EPCR in vitro and in vivo, for the first time. First, we monitored the effects of post-treatment fisetin on lipopolysaccharide (LPS) and cecal ligation and puncture (CLP)-mediated release of HMGB1 and HMGB1-mediated regulation of pro-inflammatory responses in human umbilical vein endothelial cells (HUVECs) and septic mice. Post-treatment fisetin was found to suppress LPS-mediated release of HMGB1 and HMGB1-mediated cytoskeletal rearrangements. Fisetin also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in septic mice. Fisetin induced potent inhibition of phorbol-12-myristate 13-acetate (PMA) and CLP-induced EPCR. Fisetin also inhibited the expression and activity of tumor necrosis factor-α converting enzyme, induced by PMA in endothelial cells. In addition, fisetin inhibited the production of tumor necrosis factor-α and the activation of AKT, nuclear factor-κB, and extracellular regulated kinases 1/2 by HMGB1 in HUVECs. Fisetin also down-regulated CLP-induced release of HMGB1, production of interleukin 1β, and reduced septic mortality. Collectively, these results suggest that fisetin may be a candidate therapeutic agent for the treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.
AuthorsHayoung Yoo, Sae-Kwang Ku, Min-Su Han, Kyung-Min Kim, Jong-Sup Bae
JournalInflammation (Inflammation) Vol. 37 Issue 5 Pg. 1560-74 (Oct 2014) ISSN: 1573-2576 [Electronic] United States
PMID24706001 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Flavonoids
  • Flavonols
  • HMGB1 Protein
  • HMGB1 protein, mouse
  • fisetin
Topics
  • Animals
  • Cell Movement (drug effects, physiology)
  • Dose-Response Relationship, Drug
  • Flavonoids (pharmacology, therapeutic use)
  • Flavonols
  • HMGB1 Protein (antagonists & inhibitors, metabolism)
  • Human Umbilical Vein Endothelial Cells (drug effects, metabolism)
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Sepsis (drug therapy, metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: